116 related articles for article (PubMed ID: 29738338)
1. Growth arrest and apoptosis induced by kinesin Eg5 inhibitor K858 and by its 1,3,4-thiadiazoline analogue in tumor cells.
Giantulli S; De Iuliis F; Taglieri L; Carradori S; Menichelli G; Morrone S; Scarpa S; Silvestri I
Anticancer Drugs; 2018 Aug; 29(7):674-681. PubMed ID: 29738338
[TBL] [Abstract][Full Text] [Related]
2. The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells.
De Iuliis F; Taglieri L; Salerno G; Giuffrida A; Milana B; Giantulli S; Carradori S; Silvestri I; Scarpa S
Invest New Drugs; 2016 Aug; 34(4):399-406. PubMed ID: 26994617
[TBL] [Abstract][Full Text] [Related]
3. The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells.
Taglieri L; Rubinacci G; Giuffrida A; Carradori S; Scarpa S
Invest New Drugs; 2018 Feb; 36(1):28-35. PubMed ID: 28965307
[TBL] [Abstract][Full Text] [Related]
4. Kinesin Eg5 Targeting Inhibitors as a New Strategy for Gastric Adenocarcinoma Treatment.
Marconi GD; Carradori S; Ricci A; Guglielmi P; Cataldi A; Zara S
Molecules; 2019 Oct; 24(21):. PubMed ID: 31683688
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treatment of prostate cancer and melanoma.
De Monte C; Carradori S; Secci D; D'Ascenzio M; Guglielmi P; Mollica A; Morrone S; Scarpa S; Aglianò AM; Giantulli S; Silvestri I
Eur J Med Chem; 2015 Nov; 105():245-62. PubMed ID: 26498571
[TBL] [Abstract][Full Text] [Related]
6. A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models.
Ye XS; Fan L; Van Horn RD; Nakai R; Ohta Y; Akinaga S; Murakata C; Yamashita Y; Yin T; Credille KM; Donoho GP; Merzoug FF; Li H; Aggarwal A; Blanchard K; Westin EH
Mol Cancer Ther; 2015 Nov; 14(11):2463-72. PubMed ID: 26304237
[TBL] [Abstract][Full Text] [Related]
7. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.
Nakai R; Iida S; Takahashi T; Tsujita T; Okamoto S; Takada C; Akasaka K; Ichikawa S; Ishida H; Kusaka H; Akinaga S; Murakata C; Honda S; Nitta M; Saya H; Yamashita Y
Cancer Res; 2009 May; 69(9):3901-9. PubMed ID: 19351824
[TBL] [Abstract][Full Text] [Related]
8. STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity.
Indorato RL; DeBonis S; Kozielski F; Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2013 Nov; 86(10):1441-51. PubMed ID: 24041742
[TBL] [Abstract][Full Text] [Related]
9. The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cells.
Nicolai A; Taurone S; Carradori S; Artico M; Greco A; Costi R; Scarpa S
Invest New Drugs; 2022 Jun; 40(3):556-564. PubMed ID: 35312942
[TBL] [Abstract][Full Text] [Related]
10. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.
Marcus AI; Peters U; Thomas SL; Garrett S; Zelnak A; Kapoor TM; Giannakakou P
J Biol Chem; 2005 Mar; 280(12):11569-77. PubMed ID: 15653676
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors.
Talapatra SK; Tham CL; Guglielmi P; Cirilli R; Chandrasekaran B; Karpoormath R; Carradori S; Kozielski F
Eur J Med Chem; 2018 Aug; 156():641-651. PubMed ID: 30031975
[TBL] [Abstract][Full Text] [Related]
12. Eg5 inhibitor YL001 induces mitotic arrest and inhibits tumor proliferation.
Wang Y; Wu X; Du M; Chen X; Ning X; Chen H; Wang S; Liu J; Liu Z; Li R; Fu G; Wang C; McNutt MA; Zhou D; Yin Y
Oncotarget; 2017 Jun; 8(26):42510-42524. PubMed ID: 28489567
[TBL] [Abstract][Full Text] [Related]
13. Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents.
El-Nassan HB
Eur J Med Chem; 2013 Apr; 62():614-31. PubMed ID: 23434636
[TBL] [Abstract][Full Text] [Related]
14. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities.
DeBonis S; Skoufias DA; Lebeau L; Lopez R; Robin G; Margolis RL; Wade RH; Kozielski F
Mol Cancer Ther; 2004 Sep; 3(9):1079-90. PubMed ID: 15367702
[TBL] [Abstract][Full Text] [Related]
15. Significant decrease of ADP release rate underlies the potent activity of dimethylenastron to inhibit mitotic kinesin Eg5 and cancer cell proliferation.
Sun L; Sun X; Xie S; Yu H; Zhong D
Biochem Biophys Res Commun; 2014 May; 447(3):465-70. PubMed ID: 24732354
[TBL] [Abstract][Full Text] [Related]
16. Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor.
Liu M; Yu H; Huo L; Liu J; Li M; Zhou J
Biochem Pharmacol; 2008 Jul; 76(2):169-78. PubMed ID: 18539263
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5.
Debonis S; Skoufias DA; Indorato RL; Liger F; Marquet B; Laggner C; Joseph B; Kozielski F
J Med Chem; 2008 Mar; 51(5):1115-25. PubMed ID: 18266314
[TBL] [Abstract][Full Text] [Related]
18. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520.
Tunquist BJ; Woessner RD; Walker DH
Mol Cancer Ther; 2010 Jul; 9(7):2046-56. PubMed ID: 20571074
[TBL] [Abstract][Full Text] [Related]
19. Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features.
Guido BC; Ramos LM; Nolasco DO; Nobrega CC; Andrade BY; Pic-Taylor A; Neto BA; Corrêa JR
BMC Cancer; 2015 Apr; 15():283. PubMed ID: 25885813
[TBL] [Abstract][Full Text] [Related]
20. A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor.
Xing ND; Ding ST; Saito R; Nishizawa K; Kobayashi T; Inoue T; Oishi S; Fujii N; Lv JJ; Ogawa O; Nishiyama H
Asian J Androl; 2011 Mar; 13(2):236-41. PubMed ID: 21297652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
